Structural Aspects of the ROS1 Kinase Domain and Oncogenic Mutations
Source abstract
Abstract
Protein kinases function as pivotal regulators in biological events, governing essential cellular processes through the transfer of phosphate groups from ATP molecules to substrates. Dysregulation of kinase activity is frequently associated with cancer, ocasionally arising from chromosomal translocation events that relocate genes encoding kinases. Fusion proteins resulting from such events, particularly those involving the proto-oncogene tyrosine-protein kinase ROS (ROS1), manifest as constitutively active kinases, emphasizing their role in oncogenesis. Notably, the chromosomal reallocation of the ros1 gene leads to fusion of proteins with the ROS1 kinase domain, implicated in various cancer types. Despite their prevalence, targeted inhibition of these fusion proteins relies on repurposed kinase inhibitors. This review comprehensively surveys experimentally determined ROS1 structures, emphasizing the pivotal role of X-ray crystallography in providing high-quality insights. We delve into the intricate interactions between ROS1 and kinase inhibitors, shedding light on the structural basis for inhibition. Additionally, we explore point mutations identified in patients, employing molecular modeling to elucidate their structural impact on the ROS1 kinase domain. By integrating structural insights with in vitro and in silico data, this review advances our understanding of ROS1 kinase in cancer, offering potential avenues for targeted therapeutic strategies.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Lung Cancer Treatments and Mutations · PI3K/AKT/mTOR signaling in cancer · Cancer-related gene regulation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, 9700 AB Groningen, The Netherlands
Knowledge Center Biobased Economy, Hanze University for Applied Sciences, Zernikeplein 11, 9747 AS Groningen, The Netherlands
Funding
University of Groningen
References (38)
Show source-provided references
1. Understanding and targeting resistance mechanisms in NSCLC10.1038/nrc.2017.84 ↗
2. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer10.1038/nature05945 ↗
3. Different types of ROS1 fusion partners yield comparable efficacy to crizotinib10.3727/096504019X15509372008132 ↗
4. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors10.1073/pnas.1515281112 ↗
5. Acquired resistance to crizotinib from a mutation in CD74–ROS110.1056/NEJMoa1215530 ↗
6. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations10.1073/pnas.1420785112 ↗
7. Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins10.1073/pnas.1319583110 ↗
8. Comprehensive characterization of cancer driver genes and mutations10.1016/j.cell.2018.02.060 ↗
9. Afatinib in osimertinib-resistant EGFR ex19del/T790M/P794L mutated NSCLC10.1016/j.jtho.2018.04.020 ↗
10. Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed10.1016/j.jsb.2015.10.018 ↗
11. The target landscape of clinical kinase drugs10.1126/science.aan4368 ↗
12. Virtual screening in the cloud identifies potent and selective ROS1 kinase inhibitors10.1021/acs.jcim.2c00644 ↗
13. Modeling conformational transitions in kinases by molecular dynamics simulations: Achievements, difficulties, and open challenges
14. Vilachã, J.F., Mitchel, S.C., Akele, M.Z., Evans, S., and Groves, M.R. (2020). Making NSCLC crystal clear: How kinase structures revolutionized lung cancer treatment. Crystals, 10.10.3390/cryst10090725 ↗
15. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal–epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)10.1021/jm2007613 ↗
16. Molecular simulation studies on the binding selectivity of Type-I inhibitors in the complexes with ROS1 versus ALK10.1021/acs.jcim.7b00019 ↗
17. Detailed structural investigation of Crizotinib and the exploration of its antitumor potential by DFT calculations and molecular docking10.1016/j.molstruc.2021.131530 ↗
18. The underlying mechanisms of lorlatinib penetration across the blood–brain barrier and the distribution characteristics of lorlatinib in the brain10.1002/cam4.3061 ↗
19. Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib10.1038/ncomms15761 ↗
20. DFG-1 Binding: A New Residue for Developing Selective Kinase Inhibitors10.1021/acs.jmedchem.0c01501 ↗
21. Reviving B-Factors: Retrospective normalized B-factor analysis of c-ros oncogene 1 receptor tyrosine kinase and anaplastic lymphoma kinase L1196M with crizotinib and lorlatinib10.1021/acsmedchemlett.8b00147 ↗
22. Systematic investigation of docking failures in large-scale structure-based virtual screening10.1021/acsomega.2c05826 ↗
23. Virtual screening in the cloud: How big is big enough?10.1021/acs.jcim.9b00779 ↗
24. Discovery of entrectinib: A new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (Pan-TRKs) inhibitor10.1021/acs.jmedchem.6b00064 ↗
25. Prioritizing the Catalytic Gatekeepers through Pan-Inhibitory Mechanism of Entrectinib against ALK, ROS1 and TRKA Tyrosine Kinases10.1007/s12013-021-01052-2 ↗
26. The conformational plasticity of protein kinases10.1016/S0092-8674(02)00741-9 ↗
27. Structural and molecular insight into resistance mechanisms of first generation cMET inhibitors10.1021/acsmedchemlett.9b00276 ↗
28. Targeting gatekeeper mutations for kinase drug discovery10.1021/acs.jmedchem.2c01361 ↗
29. Gaining insight into crizotinib resistance mechanisms caused by L2026M and G2032R mutations in ROS1 via molecular dynamics simulations and free-energy calculations10.1007/s00894-017-3314-z ↗
30. Molecular modeling of ALK L1198F and/or G1202R mutations to determine differential crizotinib sensitivity10.1038/s41598-019-46825-1 ↗
31. Molecular mechanism behind the resistance of the G1202R-Mutated anaplastic lymphoma kinase to the approved drug Ceritinib10.1021/acs.jpcb.8b02040 ↗
32. Sun, H., Li, Y., Tian, S., Wang, J., and Hou, T. (2014). P-loop conformation governed crizotinib resistance in G2032R-mutated ROS1 tyrosine kinase: Clues from free energy landscape. PLoS Comput. Biol., 10.10.1371/journal.pcbi.1003729 ↗
33. Investigation on the binding mechanism of loratinib with the c-ros oncogene 1 (ROS1) receptor tyrosine kinase via molecular dynamics simulation and binding free energy calculations10.1080/07391102.2017.1378127 ↗
34. A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer10.1158/1078-0432.CCR-15-2013 ↗
35. Tamirat, M.Z., Kurppa, K.J., Elenius, K., and Johnson, M.S. (2021). Structural basis for the functional changes by EGFR exon 20 insertion mutations. Cancers, 13.10.3390/cancers13051120 ↗
36. Crizotinib-resistant ROS1 mutations reveal a predictive kinase inhibitor sensitivity model for ROS1-and ALK-rearranged lung cancers10.1158/1078-0432.CCR-16-0917 ↗
37. ROS1-dependent cancers—Biology, diagnostics and therapeutics10.1038/s41571-020-0408-9 ↗
38. ROS-1 fusions in non-small-cell lung cancer: Evidence to date10.3390/curroncol29020057 ↗